Differences between the bisphosphonates for the prevention and treatment of osteoporosis

Therapeutics and Clinical Risk Management

Volumn 2, Issue 1, 2006, Pages 77-86

  Grey, Andrew ^a   Reid, Ian R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Bisphosphonates; Bone resorption; Fracture; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; GLUCOCORTICOID; IBANDRONIC ACID; NITROGEN; PAMIDRONIC ACID; PARATHYROID HORMONE; PYROPHOSPHORIC ACID DERIVATIVE; RALOXIFENE; RISEDRONIC ACID; ZOLEDRONIC ACID;

BONE NECROSIS; BONE PAIN; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIGESTIVE SYSTEM ULCER; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; FRAGILITY FRACTURE; GASTROINTESTINAL IRRITATION; HUMAN; JAW DISEASE; MUSCULOSKELETAL DISEASE; MYALGIA; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; OSTEOMALACIA; OSTEOPOROSIS; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK REDUCTION; UPPER GASTROINTESTINAL TRACT; VERTEBRA FRACTURE;

EID: 33745451165     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Adachi JD, Saag KG, Delmas PD, et al. 2001. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum, 44:202-11.
2. Bagan JV, Murillo J, Jimenez Y, et al. 2005. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med, 34:120-3.
3. Bauss F, Russell RG. 2004. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int, 15:423-33.
4. Black D, Schwartz A, Ensrud, KE, et al. 2004. A 5 year randomized trial of the long-term efficacy and safety of alendronate: The FIT Long-term EXtension (FLEX). J Bone Miner Res, 19(Suppl 1):S45.
5. Black DM, Bilezikian JP, Ensrud KE, et al. 2005. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med, 353:555-65.
6. Black DM, Cummings SR, Karpf DB, et al. 1996. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet, 348:1535-41.
7. Black DM, Greenspan SL, et al. 2003. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med, 349, 1207-15.
8. Black DM, Thompson DE, Bauer DC, et al. 2000. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab, 85:4118-24.
9. Boivin G, Meunier PJ 2002. Changes in bone remodeling rate influence the degree of mineralization of bone. Connect Tissue Res, 43:535-7.
10. Bone HG, Hosking D, Devogelaer JP, et al; Alendronate Phase III Osteoporosis Treatment Study Group. 2004. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med, 350, 1189-99.
11. Boonen S, Laan RF, Barton IP, et al. 2005. Effect of osteoporosis treatments on risk of nonvertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int, 16:1291-8.
12. Borah B, Dufresne TE, Chmielewski PA, et al. 2004. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone, 34:736-46.
13. Borah B, Dufresne TE, Cockman MD, et al. 2000. Evaluation of changes in trabecular bone architecture and mechanical properties of minipig vertebrae by three-dimensional magnetic resonance microimaging and finite element modeling. J Bone Miner Res, 15:1786-97.
14. Brown JP, Kendler DL, McClung MR, et al. 2002. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int, 71:103-11.
15. Chesnut CH, Ettinger MP, Miller PD, et al. 2005. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr Med Res Opin, 21:391-401.
16. Chesnut CH, Skag A, Christiansen C, et al. 2004. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res, 19:1241-9.
17. Cosman F, Nieves J, Zion M, et al. 2005. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med, 353: 566-75.
18. Cramer JA, Amonkar MM, Hebborn A, et al. 2005. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin, 21:1453-60.
19. Cranney A, Guyatt G, Griffith L, et al; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. 2002. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev, 23:570-8.
20. Cranney A, Tugwell P, Adachi J, et al; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. 2002. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev, 23:517-23.
21. Cranney A, Wells G, Willan A, et al; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. 2002. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev, 23,508-16.
22. Cummings SR, Black DM, Thompson DE, et al. 1998. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA, 280:2077-82.
23. Durie BG, Katz M, Crowley J. 2005. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med, 353:99-102.
24. Ensrud KE, Barrett-Connor EL, Schwartz A, et al; Fracture Intervention Trial Long-Term Extension Research Group. 2004. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res, 19:1259-69.
25. Ettinger B, Pressman A, Schein J. 1998. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Manag Care, 4: 1377-82.
26. Ettinger B, San Martin J, Crans G, et al. 2004. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res, 19:745-51.
27. Finkelstein JS, Hayes A, Hunzelman JL, et al. 2003. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med, 349, 1216-1226.
28. Fleisch H, Russell RG, Francis MD. 1969. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science, 165:1262-4.
29. Francis MD, Russell RG, Fleisch H. 1969. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science, 165:1264-6.
30. Frediani B, Falsetti P, Baldi F, et al. 2003. Effects of 4-year treatment with once-weekly clodronate on prevention of corticosteroid-induced bone loss and fractures in patients with arthritis: evaluation with dual-energy X-ray absorptiometry and quantitative ultrasound. Bone, 33:575-81.
31. Harris ST, Watts NB, Genant HK, et al. 1999. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA, 282:1344-52.
32. Heaney RP, Zizic TM, Fogelman I, et al. 2002. Risedronate reduces the risk of first vertebral fracture in osteoporotic women. Osteoporos Int, 13:501-5.
33. Hellstein JW, Marek CL 2005. Bisphosphonate osteochemonecrosis (bisphossyjaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg, 63:682-9.
34. Hosking D, Adami S, Felsenberg D, et al. 2003. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. Curr Med Res Opin, 19, 383-94.
35. Kanis JA, Oden A, Johnell O, et al. 2002. Uncertain future of trials in osteoporosis. Osteoporos Int, 13:443-9.
36. Lanza F. 2003. Bisphosphonate mucosal injury - the end of the story? Digestive & Liver Disease, 35:67-70.
37. Lanza FL. 2002. Gastrointestinal adverse effects of bisphosphonates: etiology, incidence and prevention. Treat Endocrinol, 1:37-43. Erratum. Treat Endocrinol, 1:210.
38. Lanza FL, Hunt RH, Thomson AB, et al. 2000. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology, 119: 631-8.
39. Lehenkari PP, Kellinsalmi M, Napankangas JP, et al. 2002. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol, 61:1255-62.
40. Liberman UA, Weiss SR, Broll J, et al. 1995. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med, 333:1437-43.
41. Lufkin EG, Argueta R, Whitaker MD, et al. 1994. Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporos Int, 4:320-2.
42. Masarachia P, Weinreb M, Balena R, et al. 1996. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone, 19:281-90.
43. McClung MR, Geusens P, Miller PD, et al; Hip Intervention Program Study Group. 2001. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med, 344:333-40.
44. Miller PD, McClung MR, Macovei L, et al. 2005. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res, 20:1315-22.
45. Orwoll E, Ettinger M, Weiss S, et al. 2000. Alendronate for the treatment of osteoporosis in men. N Engl J Med, 343:604-10.
46. Pecherstorfer M, Ludwig H, Schlosser K, et al. 1996. Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection. J Bone Miner Res, 11:587-93.
47. Pols HAP, Felsenberg D, Hanley DA, et al. 1999. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int, 9:461-8.
48. Purcell PM, Boyd IW. 2005. Bisphosphonates and osteonecrosis of the jaw. Med J Aust, 182:417-18.
49. Recker R, Stakkestad JA, Chesnut CH 3rd, et al. 2004. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone, 34: 890-9.
50. Reginster J, Minne HW, Sorensen OH, et al. 2000. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int, 11: 83-91.
51. Reid DM, Adami S, Devogelaer JP, et al. 2001. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int, 69:242-7.
52. Reid IR, Brown JP, Burckhardt P, et al. 2002. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med, 346:653-61.
53. Rizzoli R, Greenspan SL, Bone G 3rd, et al; Alendronate Once-Weekly Study Group. 2002. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res, 17:1988-96.
54. Rogers MJ. 2004. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates. Calcif Tissue Int, 75:451-61.
55. Rosen CJ, Hochberg MC, Bonnick SL, et al; Fosamax Actonel Comparison Trial Investigators. 2005. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res, 20:141-51.
56. Russell RG, Croucher PI, Rogers MJ. 1999. Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int, 9:566-80.
57. Simon JA, Lewiecki EM, Smith ME, et al. 2002. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clinical Therapeutics, 24:1871-86.
58. Sorensen OH, Crawford GM, Mulder H, et al. 2003. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone, 32:120-6.
59. Storm T, Thamsborg G, Steiniche T, et al. 1990. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med, 322:1265-71.
60. Tanko LB, McClung MR, Schimmer RC, et al. 2003. The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast. Bone, 32:421-6.
61. Thomson AB, Marshall JK, Hunt RH, et al; Risedronate Endoscopy Study Group. 2002. 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status. J Rheumatol, 29:1965-74.
62. Van Beek ER, Lowik CW, Papapoulos SE. 2002. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors. Bone, 30:64-70.
63. Wallach S, Cohen S, Reid DM, et al. 2000. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int, 67:277-85.
64. Wehren LE, Hosking D, Hochberg MC, et al. 2004. Putting evidence-based medicine into clinical practice: comparing antiresorptive agents for the treatment of osteoporosis. Curr Med Res Opin, 20:525-31.
65. Wysowski DK, Chang JT. 2005. Alendronate and risedronate: Reports of severe bone, joint, and muscle pain. Arch Intern Med, 165:346-7.